First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)-Reference-Cited by-同舟云学术

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

Published:2018-03-24 Issue:8 Volume:67 Page:1161-1167
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Matheron Sophie¹²³,Descamps Diane¹²³,Gallien Sebastien⁴,Besseghir Amel⁵,Sellier Pierre⁶,Blum Laurent⁷,Mortier Emmanuel⁸,Charpentier Charlotte¹²³,Tubiana Roland⁹,Damond Florence¹²³,Peytavin Gilles¹²³,Ponscarme Diane⁴,Collin Fideline⁵,Brun-Vezinet Francoise³,Chene Genevieve⁵,Matheron S,Boue F,Goujard C,Weiss L,Rami A,Mortier E,Tubiana R,Campa P,Ponscarme D,Piroth L,Miailhes P,Reynes J,Blum L,Khuong M -A,Patey O,Elharrar B,Beck-Wirth G,Fialaire P,Amri I,Cardon F,Marchand L,

Affiliation:

1. Hopital Bichat-Claude Bernard, Assistance Publique–Hôpitaux de Paris (AP-HP)

2. Institut national de la santé et de la recherche médicale (INSERM), Infection, Antimicrobiens, Modélisation, Evolution, Unité Mixte de Recherche (UMR) 1137

3. Université Paris Diderot, Sorbonne Paris Cité

4. Hopital Saint Louis, AP-HP, Paris

5. INSERM, Bordeaux Population Health Research Center, UMR 1219, Université Bordeaux, Institut de santé publique, d'épidémiologie et de développement, Centre Hospitalier Universitaire Bordeaux

6. Hopital Lariboisière, AP-HP, Paris

7. Centre Hospitalier René Dubos, Pontoise

8. Hôpital Louis Mourier, AP-HP, Colombes

9. Hopital Pitié-Salpetriere, AP-HP, Université Paris 6, INSERM, Institut Pierre-Louis Epidémiologie et Santé Publique, UMR en Santé 1136, Paris, France

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/67/8/1161/25849339/ciy245.pdf

Reference38 articles.

1. Reduced rate of disease development after HIV-2 infection as compared to HIV-1;Marlink;Science,1994

2. HIV-2-infected patients survive longer than HIV-1-infected patients;Whittle;AIDS,1994

3. Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort;Thiébaut;AIDS,2011

4. Plasma HIV-2 RNA according to CD4 count strata among HIV-2-infected adults in the IeDEA West Africa Collaboration;Ekouévi;PLoS One,2015

5. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection;MacNeil;J Virol,2007

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial;The Lancet HIV;2024-06

2. Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review;Infectious Diseases and Therapy;2024-05-09

3. Dolutegravir-based Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 (HIV-2) Infection: Progress for People With HIV-2;Clinical Infectious Diseases;2023-06-08

4. Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study;Clinical Infectious Diseases;2023-06-08

5. Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds;International Journal of Molecular Sciences;2023-03-21